<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.07916.008</object-id><label>Table 1.</label><caption><p>Donors included in the study.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.07916.008">http://dx.doi.org/10.7554/eLife.07916.008</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">All donors</th><th>cHCV</th><th>SVR</th><th>HD</th></tr><tr><th>n=29</th><th>n=37</th><th>n=25</th></tr></thead><tbody><tr><td>Male, n (%)</td><td>16 (55)</td><td>21 (57)</td><td>12 (48)</td></tr><tr><td>Age, years, median (IQR1-3)</td><td>48 (42-55)</td><td>48 (44-58)</td><td>38 (31-46)</td></tr><tr><td>IgG anti-CMV positive, n (%)</td><td>14 (48)</td><td>24 (51)</td><td>11 (44)</td></tr><tr><td>Cirrhosis, n (%)</td><td>5 (17)</td><td>8 (22)</td><td>na</td></tr><tr><td>Treatment experienced, n (%)</td><td>18 (62)</td><td>37 (100)</td><td>na</td></tr><tr><td>Treatment (n per type: 0/1/2/3)</td><td>11/12/6/0</td><td>0/26/10/1</td><td>na</td></tr><tr><td>Delay post-treatment, years, median (IQR1-3)</td><td>3.8 (3.4-4.2)</td><td>1.7 (0.9-3.2)</td><td>na</td></tr></tbody></table></table-wrap>